Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates
Authors
Keywords
-
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 21, Issue 7, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-27
DOI
10.1007/s11864-020-00754-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
- (2020) Hans Gelderblom et al. BRITISH JOURNAL OF CANCER
- Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
- (2019) Bryan D. Smith et al. CANCER CELL
- Gastrointestinal stromal tumor – A review of clinical studies
- (2019) Ardavan Khoshnood JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- KIT-dependent and -independent genomic heterogeneity of resistance in gastrointestinal stromal tumors - TORC1/2 inhibition as salvage strategy
- (2019) Thomas Mühlenberg et al. MOLECULAR CANCER THERAPEUTICS
- Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses
- (2019) Hyungwoo Cho et al. ONCOLOGIST
- Therapeutic Drug Monitoring Of Sunitinib in Gastrointestinal Stromal Tumors and Metastatic Renal Carcinoma in Adults - A Review
- (2019) Regina Demlová et al. THERAPEUTIC DRUG MONITORING
- Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors
- (2019) César Serrano et al. CLINICAL CANCER RESEARCH
- Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2018) P G Casali et al. ANNALS OF ONCOLOGY
- Radiotherapy for Gastrointestinal Stromal Tumors
- (2018) EmineElif Ozkan CHINESE MEDICAL JOURNAL
- Surgical management of metastatic gastrointestinal stromal tumour
- (2018) Yvonne Schrage et al. EJSO
- 1601ONatural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017
- (2018) J-Y Blay et al. ANNALS OF ONCOLOGY
- Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations
- (2016) Yemarshet K. Gebreyohannes et al. MOLECULAR CANCER THERAPEUTICS
- Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors
- (2015) N. A. Cohen et al. CANCER RESEARCH
- Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis
- (2015) Gloria Ravegnini et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial
- (2014) V. Gotta et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy
- (2014) T. Van Looy et al. CLINICAL CANCER RESEARCH
- Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies
- (2014) Nicolas Widmer et al. EUROPEAN JOURNAL OF CANCER
- Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor
- (2014) Jason K Sicklick et al. Journal of Translational Medicine
- Rechallenge with imatinib in GIST: is more always RIGHT?
- (2014) Damien Urban et al. LANCET ONCOLOGY
- Gastrointestinal stromal tumors: what do we know now?
- (2014) Christopher L Corless MODERN PATHOLOGY
- O2-026 * A PHASE 1 STUDY OF CABOZANTINIB IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS: ANTI-TUMOR ACTIVITY IN NSCLC AND GIST
- (2013) H. Nokihara et al. ANNALS OF ONCOLOGY
- High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors
- (2013) Helen Künstlinger et al. HUMAN PATHOLOGY
- Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
- (2013) Yoon-Koo Kang et al. LANCET ONCOLOGY
- A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST
- (2010) Jean-Yves Blay CANCER TREATMENT REVIEWS
- Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma
- (2010) R.L. Jones et al. EJSO
- Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
- (2009) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor
- (2008) Toshirou Nishida et al. CANCER SCIENCE
- Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now